Eli Lilly Joins $1T Market Cap Club, As Share Price Target Raised

Eli Lilly shares are trading 1.22% higher today, as BofA raised its price target on to $1,251 from $1,133 while maintaining a Buy rating, citing expectations that U.S. GLP-1 market sales will roughly double by 2033 with Lilly positioned as the primary beneficiary.

The upgrade comes as LLY shares have rallied 24% over the past month, pushing the pharmaceutical giant’s valuation to levels that reflect extraordinary confidence in its obesity and diabetes franchise.

Today’s move puts LLY back in the $1trillion market cap club, with the $1,000 share price looking to setup as support.

Driving The Rally

Eli Lilly shares have been on a remarkable run, climbing nearly 24% in the past 30 days as markets digest a series of positive catalysts ranging from blockbuster earnings to breakthrough pipeline data. The stock’s momentum has been fueled by growing conviction that the company’s GLP-1 franchise, anchored by Mounjaro and Zepbound, represents a multi-decade growth opportunity rather than a transient trend. BofA’s new $1,251 target joins a cluster of bullish Wall Street forecasts, with several major firms now projecting 12-month targets between $1,200 and $1,400, well above current trading levels.

The price target increase reflects a fundamental re-rating of Lilly’s earnings power. BofA’s thesis centers on sustained volume growth in GLP-1-based therapies for obesity and diabetes, with the firm expecting Lilly to maintain its leading share in the U.S. market despite intensifying competition from rivals including Novo Nordisk. The analyst pointed to the breadth of Lilly’s obesity and diabetes portfolio, spanning injectable products, the newly approved oral GLP-1 Foundayo, and next-generation candidates like retatrutide, as key differentiators that should protect market position over the coming decade.

Strong Fundamentals

The optimism is grounded in concrete financial results. In its first quarter 2026 earnings report released April 30, Lilly delivered revenue of $19.8 billion, up 56% year-over-year, driven overwhelmingly by GLP-1 volume growth. Key products revenue reached $13.4 billion in the quarter, with the combined Mounjaro and Zepbound franchise alone tracking at an annualized run-rate exceeding $50 billion based on the $12.8 billion generated in Q1. Management raised full-year 2026 guidance by approximately $2 billion following the beat, signaling confidence in sustained momentum.

The company’s newly launched oral GLP-1, Foundayo (orforglipron), represents another layer of growth potential. Approved earlier this year for obesity and overweight indications, the pill offers an alternative for patients who are injection-averse, potentially broadening the addressable market. While early prescription data came in below some sell-side expectations, management guided to “step-changes” in uptake during May and June, suggesting the launch curve is beginning to inflect upward. BofA had previously raised its target to around $1,294 shortly after Foundayo’s approval, highlighting the incremental earnings power from the new product.

Pipeline Advances

Beyond the commercial products already on the market, Lilly’s next-generation pipeline is delivering data that further validates the long-term GLP-1 thesis. On May 21, the company announced Phase 3 results for retatrutide, a triple agonist (GLP-1, GIP, glucagon) that achieved approximately 28% weight loss over roughly 18 months,a degree of efficacy comparable to bariatric surgery. The data suggests that Lilly’s obesity franchise has room to evolve beyond current GLP-1s, offering patients progressively more effective options and potentially capturing individuals who might otherwise pursue surgical intervention.

Retatrutide’s performance addresses a key bear concern: that current GLP-1 therapies might have a finite ceiling of efficacy, limiting the total addressable market. With two additional late-stage trials ongoing and a potential FDA submission planned for as early as year-end 2026, the drug could provide a significant line extension and upgrade path for existing GLP-1 users. The prospect of surgery-level weight loss from a pharmaceutical intervention supports BofA’s view that the obesity market can sustain high growth rates through 2033 and beyond.

Volume Over Pricing

This “volume over pricing” framework is central to understanding both the bull and bear cases. Lilly’s earnings show explosive unit growth in Mounjaro and Zepbound, even as management acknowledges some price compression. For bulls, this trade-off is acceptable: as long as the volume ramp remains steep, revenue and earnings per share can grow quickly, and volume-driven stories may prove more durable as payers and governments accept lower prices in exchange for broad public-health benefits. BofA’s updated target implicitly leans into this model, projecting significant U.S. GLP-1 sales growth through 2033 even if net pricing gradually normalizes.

Bears counter that investors must accept that peak margin assumptions may need to be revised downward over time, particularly as public payers like Medicare take a larger share of the mix. Long-term models that assume both explosive volume and stable high pricing are likely too optimistic, they argue. As GLP-1s become a larger line item for Medicare and Medicaid, political scrutiny of manufacturer pricing and profits may intensify, creating regulatory risk that is difficult to quantify. Small changes in long-term assumptions around market size, price per script, and therapy duration can have large effects on justified valuations, making Lilly a high-conviction but high-expectation stock.